Managing Thrombosis in Cancer Patients

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Benjamin J. Golas, MD

June 30th 2025

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

ONCOLOGY Staff

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved a 1-year event-free survival.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.

Related Content

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Benjamin J. Golas, MD

June 30th 2025

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

ONCOLOGY Staff

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.